Picture of hVIVO logo

HVO hVIVO News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapHigh Flyer

REG - hVIVO plc - 2015 Annual Report and Financial Statements <Origin Href="QuoteRef">HVO.L</Origin>

RNS Number : 6990W
hVIVO plc
28 April 2016

For immediate release 2.00pm: 28 April 2016

HVIVO PLC

("hVIVO" or the "Company")

2015 Annual Report and Financial Statements

hVIVO plc (AIM: HVO), the pioneer of human models of disease, is pleased to announce that its Annual Report and Financial Statements for the year ended 31 December 2015 is being posted to shareholders today. It will be available on the Company's website (http://hvivo.com/investors/financial-reports/) from 4.30 pm today.

For further information please contact:

hVIVO plc +44 207 756 1300

Kym Denny (Chief Executive Officer)

Graham Yeatman (Chief Financial & Business Officer)

Media Enquiries+44 203 021 3933 / +44 7854 979 420

Colin Paterson (Director of Marketing, Communication and Public Relations)

Numis Securities Limited +44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Michael Burke (Corporate Broking)

Notes to Editors:

hVIVO plc ("hVIVO") is a life sciences company pioneering a technology platform of human disease models to accelerate drug discovery and development in respiratory and infectious diseases, including flu, RSV, asthma and common cold. hVIVO has commercialised four disease models, successfully enrolled over 2,000 subjects and conducted over 40 product validation studies for a wide range of industry, government and academic clients and collaborators.


This information is provided by RNS
The company news service from the London Stock Exchange
END
ACSAKFDKNBKDNQB

Recent news on hVIVO

See all news